LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approach

Abstract This study investigates the role of MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) in endometrial cancer, focusing on its expression levels, prognostic significance, and functional impact on tumor biology. RT-qPCR analysis revealed significant upregulation of MALAT1 in endo...

Full description

Saved in:
Bibliographic Details
Main Authors: Xinlian Liu, JinBao Xiao, Junqi Ma
Format: Article
Language:English
Published: Springer 2025-07-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-02748-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849768959887278080
author Xinlian Liu
JinBao Xiao
Junqi Ma
author_facet Xinlian Liu
JinBao Xiao
Junqi Ma
author_sort Xinlian Liu
collection DOAJ
description Abstract This study investigates the role of MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) in endometrial cancer, focusing on its expression levels, prognostic significance, and functional impact on tumor biology. RT-qPCR analysis revealed significant upregulation of MALAT1 in endometrial cancer tissues compared to adjacent normal tissues (p < 0.001), with higher expression observed in advanced tumor stages and a correlation with lymphovascular invasion (p < 0.01). Kaplan–Meier survival analysis demonstrated that high MALAT1 expression was associated with shorter overall survival (OS) and progression-free survival (PFS) (log-rank test, p < 0.05). Functional assays indicated that MALAT1 knockdown in Ishikawa and HEC-1A cell lines resulted in decreased cell proliferation, increased apoptosis, and impaired angiogenesis (p < 0.01). Mechanistically, MALAT1 was found to act as a competing endogenous RNA (ceRNA), sponging tumor-suppressive microRNAs such as miR-200c and miR-145, thereby regulating key oncogenic pathways. Additionally, a strong positive correlation was identified between MALAT1 expression and clinical features, including VEGFA and ZEB1. Therapeutically, MALAT1 silencing using antisense oligonucleotides in a xenograft mouse model significantly reduced tumor growth and microvessel density (p < 0.01). These findings suggest that MALAT1 is a promising biomarker and therapeutic target in endometrial cancer.
format Article
id doaj-art-63ebe573319b4e3094b007cf2afde25d
institution DOAJ
issn 2730-6011
language English
publishDate 2025-07-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-63ebe573319b4e3094b007cf2afde25d2025-08-20T03:03:37ZengSpringerDiscover Oncology2730-60112025-07-0116111310.1007/s12672-025-02748-0LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approachXinlian Liu0JinBao Xiao1Junqi Ma2Department of Gynecological Oncology, The First Affiliated Hospital of Xinjiang Medical UniversityDepartment of Gynecological Oncology, The First Affiliated Hospital of Xinjiang Medical UniversityDepartment of Gynecological Oncology, The First Affiliated Hospital of Xinjiang Medical UniversityAbstract This study investigates the role of MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) in endometrial cancer, focusing on its expression levels, prognostic significance, and functional impact on tumor biology. RT-qPCR analysis revealed significant upregulation of MALAT1 in endometrial cancer tissues compared to adjacent normal tissues (p < 0.001), with higher expression observed in advanced tumor stages and a correlation with lymphovascular invasion (p < 0.01). Kaplan–Meier survival analysis demonstrated that high MALAT1 expression was associated with shorter overall survival (OS) and progression-free survival (PFS) (log-rank test, p < 0.05). Functional assays indicated that MALAT1 knockdown in Ishikawa and HEC-1A cell lines resulted in decreased cell proliferation, increased apoptosis, and impaired angiogenesis (p < 0.01). Mechanistically, MALAT1 was found to act as a competing endogenous RNA (ceRNA), sponging tumor-suppressive microRNAs such as miR-200c and miR-145, thereby regulating key oncogenic pathways. Additionally, a strong positive correlation was identified between MALAT1 expression and clinical features, including VEGFA and ZEB1. Therapeutically, MALAT1 silencing using antisense oligonucleotides in a xenograft mouse model significantly reduced tumor growth and microvessel density (p < 0.01). These findings suggest that MALAT1 is a promising biomarker and therapeutic target in endometrial cancer.https://doi.org/10.1007/s12672-025-02748-0MALAT1Endometrial cancerPrognosisCompeting endogenous RNAApoptosisAngiogenesis
spellingShingle Xinlian Liu
JinBao Xiao
Junqi Ma
LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approach
Discover Oncology
MALAT1
Endometrial cancer
Prognosis
Competing endogenous RNA
Apoptosis
Angiogenesis
title LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approach
title_full LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approach
title_fullStr LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approach
title_full_unstemmed LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approach
title_short LncRNA MALAT1 as a prognostic biomarker in endometrial cancer: a molecular genetics approach
title_sort lncrna malat1 as a prognostic biomarker in endometrial cancer a molecular genetics approach
topic MALAT1
Endometrial cancer
Prognosis
Competing endogenous RNA
Apoptosis
Angiogenesis
url https://doi.org/10.1007/s12672-025-02748-0
work_keys_str_mv AT xinlianliu lncrnamalat1asaprognosticbiomarkerinendometrialcanceramoleculargeneticsapproach
AT jinbaoxiao lncrnamalat1asaprognosticbiomarkerinendometrialcanceramoleculargeneticsapproach
AT junqima lncrnamalat1asaprognosticbiomarkerinendometrialcanceramoleculargeneticsapproach